Skip to content

Study · Animal study (in vivo) · mouse · 2021

4 results

The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain.

Li L, Yoo ES, Li X, Wyler SC, Chen X, Chen X, Wan R, Arnold AG, Birnbaum SG, Jia L, Sohn JW, Liu C

The Journal of experimental medicine12 May 2021Cited by 34 (Europe PMC)

PMID33978701 (opens in a new tab)PMCIDPMC8126977 (opens in a new tab)DOI10.1084/jem.20202484 (opens in a new tab)PepBankPUB-33978701
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In risperidone-fed mice, setmelanotide mitigated hyperphagia.

    In plain wordsIn mice fed risperidone, setmelanotide reduced excessive eating.

    Peptide
    Setmelanotide
    Outcome
    DecreaseHyperphagia in risperidone-fed mice
    Study

    mousen: not reported in source

    Antipsychotic-fed mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, we showed that treatment with setmelanotide, an MC4R-specific agonist, mitigated hyperphagia and obesity in both risperidone- and olanzapine-fed mice.
    1 context sentence
    Summary · context
    Here, we report a new mouse model that reliably reproduces risperidone-induced weight gain, adiposity, and glucose intolerance.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In risperidone-fed mice, setmelanotide mitigated obesity.

    In plain wordsIn mice fed risperidone, setmelanotide reduced obesity.

    Peptide
    Setmelanotide
    Outcome
    DecreaseObesity in risperidone-fed mice
    Study

    mousen: not reported in source

    Antipsychotic-fed mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, we showed that treatment with setmelanotide, an MC4R-specific agonist, mitigated hyperphagia and obesity in both risperidone- and olanzapine-fed mice.
    1 context sentence
    Summary · context
    Here, we report a new mouse model that reliably reproduces risperidone-induced weight gain, adiposity, and glucose intolerance.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In olanzapine-fed mice, setmelanotide mitigated hyperphagia.

    In plain wordsIn mice fed olanzapine, setmelanotide reduced excessive eating.

    Peptide
    Setmelanotide
    Outcome
    DecreaseHyperphagia in olanzapine-fed mice
    Study

    mousen: not reported in source

    Antipsychotic-fed mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, we showed that treatment with setmelanotide, an MC4R-specific agonist, mitigated hyperphagia and obesity in both risperidone- and olanzapine-fed mice.
    1 context sentence
    Summary · context
    Here, we report a new mouse model that reliably reproduces risperidone-induced weight gain, adiposity, and glucose intolerance.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In olanzapine-fed mice, setmelanotide mitigated obesity.

    In plain wordsIn mice fed olanzapine, setmelanotide reduced obesity.

    Peptide
    Setmelanotide
    Outcome
    DecreaseObesity in olanzapine-fed mice
    Study

    mousen: not reported in source

    Antipsychotic-fed mice
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, we showed that treatment with setmelanotide, an MC4R-specific agonist, mitigated hyperphagia and obesity in both risperidone- and olanzapine-fed mice.
    1 context sentence
    Summary · context
    Here, we report a new mouse model that reliably reproduces risperidone-induced weight gain, adiposity, and glucose intolerance.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.